z-logo
Premium
3D‐micro‐MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties
Author(s) -
Kobayashi Hisataka,
Sato Noriko,
Hiraga Akira,
Saga Tsuneo,
Nakamoto Yuji,
Ueda Hiroyuki,
Konishi Junji,
Togashi Kaori,
Brechbiel Martin W.
Publication year - 2001
Publication title -
magnetic resonance in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.696
H-Index - 225
eISSN - 1522-2594
pISSN - 0740-3194
DOI - 10.1002/1522-2594(200103)45:3<454::aid-mrm1060>3.0.co;2-m
Subject(s) - dendrimer , biodistribution , pharmacokinetics , chemistry , mri contrast agent , perfusion , nuclear medicine , gadolinium , medicine , radiology , pharmacology , in vitro , biochemistry , organic chemistry
Four novel macromolecular MRI contrast agents, all of which had the same chemical composition but different molecular weights, were prepared using generation‐3, ‐4, ‐5, and ‐6 polyamidoamine (PAMAM TM ) dendrimers conjugated with a bifunctional diethylenetriaminepentaacetic acid derivative to change the blood retention, tissue perfusion, and excretion. Size‐dependent changes in the pharmacokinetics were observed in the biodistribution study. 153 Gd‐labeled generation‐6 PAMAM TM ‐conjugates remained in the blood significantly longer than all of the other preparations ( P < 0.001). The increase in blood‐to‐organ ratio of the preparations was found to correlate with increasing molecular size ( P < 0.001). Additionally, 3D‐micro MR images and angiography of mice of high quality and detail were obtained using PAMAM TM ‐(1B4M‐Gd)x as a macro‐molecular MRI contrast agent with a 1.5‐T clinical MRI instrument. Numerous fine vessels of ∼200 μm diameter were visualized on subtracted 3D‐MR angiographms with G6D‐(1B4M‐Gd) 192 . The quality of the images was sufficient to estimate the microvasculature of cancerous tissue for anti‐angiogenesis therapy and to investigate knockout mice. Magn Reson Med 45:454–460, 2001. © 2001 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here